Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Oct 7

PMID 36206301

Authors

Gwo Yaw Ho

Elizabeth L Kyran

Justin Bedo

Matthew J Wakefield

Darren P Ennis

Hasan B Mirza

Cassandra J Vandenberg

Elizabeth Lieschke

Andrew Farrell

Anthony Hadla

Ratana Lim

Genevieve Dall

James E Vince

Ngee Kiat Chua

Olga Kondrashova

Rosanna Upstill-Goddard

Ulla-Maja Bailey

Suzanne Dowson

Patricia Roxburgh

Rosalind M Glasspool

Gareth Bryson

Andrew V Biankin

Susanna L Cooke

Gayanie Ratnayake

Orla McNally

Nadia Traficante

Anna DeFazio

S John Weroha

David D Bowtell

Iain A McNeish

Anthony T Papenfuss

Clare L Scott

Holly E Barker

Affiliations

Soon will be listed here.

Abstract

Significance: Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor immunity.

Citing Articles

Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

Nesic K, Rybinski K, Ratnayake G, Ho G, Lim R, Radke M Clin Transl Med. 2025; 15(3):e70274.

PMID: 40074693 PMC: 11903193. DOI: 10.1002/ctm2.70274.

Teratoma combined with struma ovarii and sarcomatoid carcinoma: a case report and review of the literature.

Qin H, Chen D, Jin S, Liu J, Gao B, Wang Y BMC Womens Health. 2024; 24(1):517.

PMID: 39277716 PMC: 11401426. DOI: 10.1186/s12905-024-03354-y.

A Novel Method for the Early Detection of Single Circulating, Metastatic and Self-Seeding Cancer Cells in Orthotopic Breast Cancer Mouse Models.

Murad M, Chen Y, Iaria J, Fonseca Teixeira A, Zhu H Cells. 2024; 13(14.

PMID: 39056749 PMC: 11275056. DOI: 10.3390/cells13141166.

CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and amplified ovarian cancer.

Xu H, Gitto S, Ho G, Medvedev S, Shield-Artin K, Kim H iScience. 2024; 27(7):109978.

PMID: 39021796 PMC: 11253285. DOI: 10.1016/j.isci.2024.109978.

Ovarian carcinosarcoma is highly aggressive compared to other ovarian cancer histotypes.

McFarlane I, Porter J, Brownsell E, Ghaoui N, Connolly K, Herrington C Front Oncol. 2024; 14:1399979.

PMID: 38854725 PMC: 11157229. DOI: 10.3389/fonc.2024.1399979.

References

Sun M, Gomes S, Chen P, Frankenberger C, Sankarasharma D, Chung C . RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2013; 33(27):3528-37. PMC: 4096871. DOI: 10.1038/onc.2013.328. View

Sreenan J, HART W . Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 1995; 19(6):666-74. View

Tanni K, Truong C, Johnson B, Qian J . Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021; 163:103375. DOI: 10.1016/j.critrevonc.2021.103375. View

Balzeau J, Menezes M, Cao S, Hagan J . The LIN28/let-7 Pathway in Cancer. Front Genet. 2017; 8:31. PMC: 5368188. DOI: 10.3389/fgene.2017.00031. View

Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S . Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer. 2014; 110(6):1497-505. PMC: 3960630. DOI: 10.1038/bjc.2014.80. View

Helland A, Anglesio M, George J, Cowin P, Johnstone C, House C . Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One. 2011; 6(4):e18064. PMC: 3076323. DOI: 10.1371/journal.pone.0018064. View

Katakami N, Felip E, Spigel D, Kim J, Olivo M, Guo M . A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer. Ann Oncol. 2017; 28(9):2241-2247. PMC: 5834051. DOI: 10.1093/annonc/mdx284. View

Schoffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E . Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028):1629-37. DOI: 10.1016/S0140-6736(15)01283-0. View

Glaser G, Weroha S, Becker M, Hou X, Enderica-Gonzalez S, Harrington S . Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One. 2015; 10(5):e0126867. PMC: 4427104. DOI: 10.1371/journal.pone.0126867. View

10.

Wang T, Wang G, Hao D, Liu X, Wang D, Ning N . Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer. 2015; 14:125. PMC: 4512107. DOI: 10.1186/s12943-015-0402-5. View

11.

Wang X, Liu X, Li A, Chen L, Lai L, Lin H . Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res. 2011; 17(8):2570-80. PMC: 3079060. DOI: 10.1158/1078-0432.CCR-10-2542. View

12.

Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A . HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology. 2012; 60(3):397-404. DOI: 10.1111/j.1365-2559.2011.04121.x. View

13.

Park S, Shell S, Radjabi A, Schickel R, Feig C, Boyerinas B . Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007; 6(21):2585-90. DOI: 10.4161/cc.6.21.4845. View

14.

Brackmann M, Stasenko M, Uppal S, Erba J, Reynolds R, McLean K . Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. BMC Cancer. 2018; 18(1):172. PMC: 5810191. DOI: 10.1186/s12885-018-4082-6. View

15.

Saada-Bouzid E, Burel-Vandenbos F, Ranchere-Vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C . Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015; 28(11):1404-14. DOI: 10.1038/modpathol.2015.96. View

16.

Alexandrova N, Niklinski J, Bliskovsky V, Otterson G, Blake M, Kaye F . The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro. Mol Cell Biol. 1995; 15(9):5188-95. PMC: 230766. DOI: 10.1128/MCB.15.9.5188. View

17.

Abeln E, Smit V, Wessels J, de Leeuw W, Cornelisse C, Fleuren G . Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours. J Pathol. 1998; 183(4):424-31. DOI: 10.1002/(SICI)1096-9896(199712)183:4<424::AID-PATH949>3.0.CO;2-L. View

18.

Morishita A, Zaidi M, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y . HMGA2 is a driver of tumor metastasis. Cancer Res. 2013; 73(14):4289-99. PMC: 3715567. DOI: 10.1158/0008-5472.CAN-12-3848. View

19.

Carmen M, Birrer M, Schorge J . Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2011; 125(1):271-7. DOI: 10.1016/j.ygyno.2011.12.418. View

20.

Huang B, Song B, Xu C . Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020; 2(2):132-141. DOI: 10.1038/s42255-020-0174-0. View